Polydex Pharmaceuticals Limited (NASDAQ: POLXF) is pleased to announce the commencement of a randomized, blinded Phase II clinical trial of Cellulose Sulphate (Ushercell), a microbicidal gel which is being tested for its effectiveness in the treatment of Bacterial Vaginosis (BV), the most common vaginal disorder among reproductive-age women, present in 15-25% of gynecologic patients and up to 60% of women seen at sexually transmitted diseases clinics. BV is also associated with increased risk of HIV acquisition and transmission.
